[Form 4] Wellgistics Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing for Clover Health Investments Corp. (CLOV) discloses three transactions by Jamie L. Reynoso, CEO – Medicare Advantage, on July 3 and July 7, 2025.

• Dispositions: 19,789 Class A shares sold on 7/3/25 at a weighted-average price of $2.58; 2,012 shares sold on 7/7/25 at $2.85. Both sales executed under a Rule 10b5-1 plan adopted 3/13/25.
• Withholding for taxes: 8,706 shares automatically withheld on 7/3/25 at $2.56 to satisfy tax obligations upon RSU vesting.
• Post-transaction ownership: Reynoso continues to hold 3,297,821 Class A shares directly.
• The RSU award that triggered the tax withholding vests quarterly through 1/3/27, subject to continued service.

No derivative security activity was reported. The transactions represent roughly 0.66 % of Reynoso’s stated post-filing stake, indicating a modest reduction in ownership.

Positive

• High residual ownership: Jamie L. Reynoso still holds 3.3 million Class A shares, maintaining strong equity alignment.

Negative

• Insider selling activity: Disposition of 21,801 shares may be perceived negatively, though size is immaterial (<1% of holding).

Insights

Financial Analyst

TL;DR: Small insider sale (<1% stake) under 10b5-1 plan; minimal impact on valuation.

The combined 21,801-share sale, worth roughly $56k, is immaterial relative to Clover’s market capitalization and to Reynoso’s 3.3 million-share holding. Execution under a pre-planned 10b5-1 agreement limits signaling value. Tax-related share withholding is standard. Overall, the filing offers few clues about near-term fundamentals.

Corporate Governance Specialist

TL;DR: Governance-neutral event; adequate disclosure, large residual stake aligns incentives.

Use of a Rule 10b5-1 plan and detailed footnotes comply with SEC best practices, reducing concerns over opportunistic trading. Reynoso’s remaining 3.3 million shares preserve alignment with shareholders. No red flags emerge, but persistent small disposals could merit trend monitoring.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PETERSON MICHAEL L

(Last) (First) (Middle)

C/O WELLGISTICS HEALTH, INC.

3000 BAYPORT DRIVE, SUITE 950

(Street)

TAMPA FL 33607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Wellgistics Health, Inc. [ WGRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2025		A		200,000(1)	D	$0.9	200,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares shall fully vest solely on the basis of the passage of time, with 66,000 shares vesting immediately, 67,000 shares vesting on July 2, 2026, and 67,000 shares vesting on July 2, 2027.

	/s/ Michael Peterson	07/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Clover Health (CLOV) shares did Jamie L. Reynoso sell?

21,801 shares were sold (19,789 on 7/3/25 and 2,012 on 7/7/25).

At what prices were the CLOV shares sold?

Weighted-average prices were $2.58 on 7/3/25 and $2.85 on 7/7/25.

Why were 8,706 CLOV shares disposed of without a sale?

They were withheld to cover taxes on the vesting of RSUs granted 1/3/23.

Does the Form 4 indicate ongoing RSU vesting for Reynoso?

Yes. The remaining RSUs vest quarterly until January 3, 2027, contingent on continued service.

What is Jamie L. Reynoso’s remaining CLOV share ownership?

After the transactions, she directly owns 3,297,821 Class A shares.

Were the sales under a Rule 10b5-1 trading plan?

Yes. Both sales were executed pursuant to a 10b5-1 plan adopted on March 13, 2025.